Clinical Scorecard: Addressing the Intersection of Diabetes and Cardiovascular Disease Prevention: Tackling Two Major Health Challenges

At a Glance

Key Highlights

• One in six patients hospitalized for myocardial infarction is newly diagnosed with diabetes, highlighting the need for improved diabetes screening.
• SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular events and are increasingly used in patients with Type 2 diabetes and heart failure.
• Novel cardiovascular risk prediction models tailored for Type 2 diabetes, such as SCORE2-diabetes, ADVANCE, and CARE-DM for elderly patients, improve risk stratification.

Guideline-Based Recommendations

Diagnosis

• Implement population-level screening for diabetes in patients with cardiovascular events such as myocardial infarction or stroke.
• Use validated cardiovascular risk prediction models specific to Type 2 diabetes (e.g., SCORE2-diabetes, ADVANCE) for risk assessment.
• Apply specialized models like CARE-DM for cardiovascular risk prediction in elderly patients with Type 2 diabetes.

Management

• Employ sodium–glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) to reduce cardiovascular events in Type 2 diabetes patients.
• Combine renin–angiotensin system inhibitors (RASi), mineralocorticoid receptor antagonists (MRA), and SGLT2i to delay chronic kidney disease progression.
• Consider individualized treatment approaches based on patient characteristics such as systolic blood pressure, BMI, and fasting plasma glucose.

Monitoring & Follow-up

• Monitor 24-hour and nocturnal heart rate variability as a predictor of microvascular complications and cardiovascular mortality.
• Regularly assess renal function and potassium levels when prescribing RASi and MRA in patients with heart failure and Type 2 diabetes.
• Track cardiovascular outcomes during GLP-1RA therapy to evaluate safety, including atrial fibrillation risk.

Risks

• Be aware that reduced heart rate variability is associated with increased cardiovascular and all-cause mortality.
• Monitor for potential underuse of mineralocorticoid receptor antagonists and renin–angiotensin system inhibitors in patients with heart failure and Type 2 diabetes.
• GLP-1 receptor agonists such as albiglutide have not shown increased risk of atrial fibrillation in clinical trials.

Patient & Prescribing Data

Patients with Type 2 diabetes, including those with heart failure and elderly patients

SGLT2 inhibitors are widely used and trusted in patients with heart failure and Type 2 diabetes; heart failure presence influences higher SGLT2i use and lower metformin use; GLP-1 receptor agonists demonstrate cardiovascular benefit without increased atrial fibrillation risk.

Clinical Best Practices

• Screen patients hospitalized for myocardial infarction or stroke for newly diagnosed diabetes to enable early intervention.
• Use diabetes-specific cardiovascular risk prediction tools to guide individualized treatment decisions.
• Incorporate SGLT2 inhibitors and GLP-1 receptor agonists early in treatment regimens for cardiovascular risk reduction.
• Adopt combination therapy with RASi, MRA, and SGLT2i to slow chronic kidney disease progression in diabetic patients.
• Monitor heart rate variability as a prognostic tool for cardiovascular and all-cause mortality risk.
• Tailor treatment choices based on individual patient characteristics such as blood pressure and metabolic parameters.

References

• Douelrachad et al., New diagnosis of diabetes in patients with myocardial infarction or stroke: a systematic review and meta-analysis
• Abushanab et al., The reduction of the productivity burden of cardiovascular disease by improving risk factor control among Australians with type 2 diabetes
• Enguita-Germán et al., External validation of cardiovascular risk scores in patients with type 2 diabetes using the Spanish population-based CARDIANA cohort
• Aponte Ribero et al., Development and validation of the CARE-DM model to predict cardiovascular risk in older persons with type 2 diabetes
• Bai et al., Advanced prediction of heart failure risk in elderly diabetic and hypertensive patients using machine learning models
• Nesti et al., Circadian heart rate fluctuations predict cardiovascular and all-cause mortality in Type 2 and Type 1 diabetes
• Musella et al., Pharmacological treatment patterns and outcomes according to coexistence of heart failure and type 2 diabetes
• Krychtiuk et al., Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease
• Halimi et al., Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease
• Mori et al., Heterogeneous cardiovascular effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes
• Jimba et al., Effect of sodium-glucose cotransporter-2 inhibitors on kidney outcomes of individuals with type 2 diabetes according to blood pressure levels